Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber

A Randomised, Placebo-controlled, 4-period, Incomplete Block, Crossover Study of 7 Days Dosing of Intranasal GW784568X (100mcg, 200mcg and 400mcg od), Fluticasone Propionate (200mcg od) and Placebo (Blinded for GW784568X vs Placebo) to Evaluate the Efficacy and Safety Using an Environmental Chamber in Male Subjects With Allergic Rhinitis

This study was designed to look at safety aspects and effects of intranasal doses of GW784568X on allergic rhinitis symptoms to develop this drug for its use in people who suffer with allergic rhinitis

A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X (100mcg, 200mcg and 400mcg od), fluticasone propionate (200mcg od) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and safety using an environmental chamber in male subjects with allergic rhinitis

Inclusion criteria:

• Healthy with exception of seasonal rhinitis. May also have mild asthma.
• Weight greater than or equal to 50kg
• Non-smoker for at least 12 months

Exclusion criteria:

• History of frequent nosebleeds
• Have participated in another trial in the last 30 days.
• Have donated blood in the previous 3 months
• Have used prescription or non prescription drugs within last 7 days
• Have history of alcohol/drug abuse within last 12 months
• Have positive Hepatitis B or C test within 3 months of screening
• Subject tested positive for HIV